This page shows the latest voxilaprevir news and features for those working in and with pharma, biotech and healthcare.
The treatment brings together sofosbuvir, velpatasvir and voxilaprevir. Gilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi (sofosbuvir/velpatasvir/voxilaprevir) as it becomes the first and
The approval is believed to be the first for voxilaprevir anywhere in the world. ... Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir therapy in the EU, winning an accelerated review from the EMA in January.
virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve
Seeks FDA approval for combination of Epclusa and voxilaprevir. The new generation of directly-acting antiviral (DAAs) have transformed the treatment of hepatitis C virus (HCV) infections - but not all patients ... inhibitor called voxilaprevir.
well as a triplet therapy based on sofosbuvir, velpatasvir and voxilaprevir that is in four late-stage trials.
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...